BOARD OF ADVISORS
Poïesis is in the process of attracting a talented and diverse board of advisors with deep experience in biotechnology, comparative internal medicine and finance. Their guidance, resources and networks will enable Poïesis to successfully execute its commercial strategy. Additional board members as well as a scientific and clinical advisory board will be added soon.
Laurent Fischer, MD – Advisor
Since March 2014 Dr. Fischer has been the Chief Executive Officer of Tobira Therapeutics, Inc. (NASDAQ: TBRA) which was acquired by Allergan plc (NYSE: AGN) in September 2016 for $1.7 billion. He has been involved in and has managed four healthcare companies. He has more than 20 years of drug development and commercial experience in the biopharmaceutical industry. Dr. Fischer co-founded Ocera Therapeutics, Inc. in 2004. He served as President and Chief Operating Officer of RxCentric.com, Inc. He served as the President and Chief Executive Officer of Ocera Therapeutics, Inc. since 2005, where he led the approval of Zysa(R), the first treatment ever approved for Irritable Bowel Syndrome in Europe and developed the first ammonia scavenger for the treatment of complications of liver disease. He served as Chief Executive Officer and President of Jennerex Biotherapeutics, Inc. He has been a Member of the Board of Directors of the AIDS Healthcare Foundation since 2001.
Dr. Fischer received his undergraduate degree from the University of Geneva and his Medical Degree (MD) from the Geneva Medical School, Switzerland.
William Symington, DVM, MBA – Advisor
Dr. Symington has over 30 years of commercial leadership experience in the global animal health industry including product development, marketing and launch at Zoetis and Pfizer Animal Health, bringing his unique skill set to bear upon strategic planning from a regulatory and commercial perspective.
Dr. Symington received his DVM from the Royal Veterinary College, London and holds an MBA from the Cranfield School of Management.
Judy Müller-Cohn, PhD – Advisor
Dr. Müller-Cohn served as the President and Chief Operating Officer of Biomatrica, Inc. until August 12th 2015. Dr. Müller-Cohn co-founded Biomatrica, Inc. in 2004 and served as its Chief Executive Officer. She has extensive experience in developing products for the life science industry to market and was involved in the development of numerous biotechnology companies. She served as a Director of Business Development at Digital Gene Technologies. Previously, she was a Scientist at Mycogen/Dow AgroSciences, where she took basic research to the market. She serves as a Director of Biomatrica, Inc. She has authored many papers and patents that paved the road to marketable products.
Dr. Müller-Cohn holds a PhD in microbial biochemistry from the Université Pierre et Marie Curie (Paris VI) in Paris, France, an MS in entomology from Oregon State University and a BA in agricultural ecology from Evergreen State College.
Piers Hartland-Swann, BSc Eng – Advisor
With more than 25 years in banking, including over 22 years in investment banking, Mr. Hartland-Swann is currently Managing Director at FirstCapital, a London-based international investment bank specialising in mergers and acquisitions, private placements and strategic advisory services in the technology, media and communications sectors. Prior to joining FirstCapital in 2008, he was a Partner at MacArthur and Co., where he focused on advising and fundraising for growth companies.
Mr. Hartland-Swann previously served as Senior Managing Director at Bear Stearns in Hong Kong, where he led the team that advised China Telecom on their US$1.4 billion IPO in 2002. Prior to this, he spent 14 years at UBS Warburg, most recently as Head of Asian Telecoms Corporate Finance in Hong Kong, advising clients such as PCCW on its US$34 billion takeover of Hong Kong Telecom; and NTT, Korea Telecom and Chunghwa Telecom on public equity offerings. Before Hong Kong, Mr. Hartland-Swann spent 6 years in Corporate Finance at UBS in London, where he advised clients in many different industry sectors including telecoms, technology, biotech, finance and transportation.
Mr. Hartland-Swann holds a BSc (Hons) in Civil Engineering from King’s College London.